The efficient tumor growth inhibition observed for fulvestrant at doses several fold lower than the 200 mg/kg dose historically used preclinically led us to evaluate the pharmacodynamic relationship between the dose administered and ER downregulation, as the clinical efficacy of fulvestrant has been attributed at least in part to its ability to reduce ER expression. This evidence concerns the gene ESR1 and neoplasm.